Stock screener

ENTX

Conviction 72HealthcareScan · Mon, Aug 10, 2026
ENTX$3.07+6.97%
ResistanceSupportVol 14
63 bars
Vol MA14 6.92M
May 11May 28Jun 16Jul 6Jul 23Aug 10
Entera Bio Ltd.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.enterabio.com ↗
Price3.07
Change+6.97%
Gap-2.44%
Rel volume0.12×
Avg volume4.92M
Avg $ vol18.53M
SMA 202.55
SMA 501.88
SMA 2001.72
Price vs 50+63.64%
Price vs 200+78.61%
MA stackbullish
50/200 crossgolden · 5d
Supertrendup · 2.39
RSI (14)65
MACD hist-0.01
MACD crossbear · 1d
Stoch %K / %D50 / 44
ADX (14)63
+DI / −DI35 / 10
RSI divergence—
MACD divergence—
ATR %+10.48%
ADR %11.56%
52w high3.92
52w low1.00
From 52w high-21.68%
Above 52w low+207.00%
New 52w highNo
SqueezeOff
Bollinger width93.77%
%B0.72
Donchian pos57.03%
Donchian high4.20
Donchian low1.57
AVWAP (52w high)3.57
vs AVWAP high-13.90%
AVWAP (52w low)2.81
vs AVWAP low+9.39%
OBV trendUp
Chaikin MF (20)0.49
Today vs 20d0.12×
Avg vol (14d)6.92M
Avg vol (20d)4.92M
Avg $ vol (20d)18.53M
Market cap531.55M
RS 3m (vs SPY)+103.79%
RS 6m (vs SPY)+131.19%
RS line new highNo
Trend template6/8
Technical rank96.3
1 week+3.72%
1 month+85.50%
3 months+136.15%
6 months+195.19%
1 year+70.56%
YTD+73.45%
P/E-46.47
P/B73.16
P/S—
P/FCF-71.09
EPS0.2500
Div yield—
ROE-157.43%
ROA-58.72%
Debt/Eq—
Current8.98
EV/EBITDA—
Gross margin0.00%
Net margin—
Rev growth-76.80%
EPS growth-19.89%
Price target9.00
Target upside193.16%
Analyst ratingBuy
Institutional16.62%
Ent. value520.24M
Revenue0
Net income-7.31M
Gross profit0
Free cash flow-7.48M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out49.29M
Employees22
ListedThu, Jun 28, 2018
Free float25.65M
Float %55.0%
Short interest297.45K
Days to cover1.3d
Short volume43.4%
Squeeze score11 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.14 vs −$0.08
Last surprise-75.0% miss
Setup gradeB
Conviction72 / 100
Pattern quality—
Tech rank96.3 / 100
Group rank86 / 100 · Leading
Status laneNo active setup
Setup direction—
Pattern family
Resistance3.49
Support1.27
Days since event—
Candle confirm—
News sentiment—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in ENTX

All disclosures →
No recent disclosed trades by Congress in ENTX. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in ENTX · 10 buys

InsiderSideShares
Ellis Sean
Director · Ordinary Shares, par value NIS 0.0000769 per share · 2026-08-07
Grant20.03K
Ellis Sean
Director · Stock Option (right to buy) · 2026-08-07
Grant40K
Burshtein Gregory
Chief of R&D · Stock Option (right to buy) · 2026-08-07
Grant180K
Germano Geno J
Director · Ordinary Shares, par value NIS 0.0000769 per share · 2026-08-07
Grant25.01K
Germano Geno J
Director · Stock Option (right to buy) · 2026-08-07
Grant50K
Germano Geno J
Director · Stock Option (right to buy) · 2026-08-07
Grant43.01K
Toledano Miranda Jayne
Chief Executive Officer · Stock Option (right to buy) · 2026-08-07
Grant500K
Toledano Miranda Jayne
Chief Executive Officer · Stock Option (right to buy) · 2026-08-07
Grant200K
Galitzer Hillel
Chief Operating Officer · Stock Option (right to buy) · 2026-08-07
Grant200K
Yaacov-Garbeli Dana
Chief Financial Officer · Stock Option (right to buy) · 2026-08-07
Grant140K

SEC filings

EDGAR filings in ENTX · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.